SE0101854L - Användning av en förening med en negativt laddad region av grupper för behandling av restenos. - Google Patents

Användning av en förening med en negativt laddad region av grupper för behandling av restenos.

Info

Publication number
SE0101854L
SE0101854L SE0101854A SE0101854A SE0101854L SE 0101854 L SE0101854 L SE 0101854L SE 0101854 A SE0101854 A SE 0101854A SE 0101854 A SE0101854 A SE 0101854A SE 0101854 L SE0101854 L SE 0101854L
Authority
SE
Sweden
Prior art keywords
negatively charged
restenosis
compound
groups
treatment
Prior art date
Application number
SE0101854A
Other languages
Unknown language ( )
English (en)
Swedish (sv)
Other versions
SE0101854D0 (sv
Inventor
Matti Juhani Siren
Original Assignee
Bioneris Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneris Ab filed Critical Bioneris Ab
Priority to SE0101854A priority Critical patent/SE0101854L/
Publication of SE0101854D0 publication Critical patent/SE0101854D0/xx
Priority to JP2002592945A priority patent/JP2004532872A/ja
Priority to ES02733745T priority patent/ES2316568T3/es
Priority to DE60230134T priority patent/DE60230134D1/de
Priority to AT02733745T priority patent/ATE415975T1/de
Priority to US10/478,962 priority patent/US20040235799A1/en
Priority to PCT/SE2002/001016 priority patent/WO2002096436A1/en
Priority to DK02733745T priority patent/DK1390045T3/da
Priority to EP02733745A priority patent/EP1390045B1/de
Publication of SE0101854L publication Critical patent/SE0101854L/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
SE0101854A 2001-05-28 2001-05-28 Användning av en förening med en negativt laddad region av grupper för behandling av restenos. SE0101854L (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0101854A SE0101854L (sv) 2001-05-28 2001-05-28 Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
JP2002592945A JP2004532872A (ja) 2001-05-28 2002-05-28 再狭窄の治療のためにラジカルの負に帯電されたドメインをもった化合物の使用
ES02733745T ES2316568T3 (es) 2001-05-28 2002-05-28 Uso de un compuesto con un dominio cargado negativamente de radicales que contiene fosforo para el tratamiento de reestenosis.
DE60230134T DE60230134D1 (de) 2001-05-28 2002-05-28 Verwendung einer verbindung mit einer negativ geladenen domäne von phosphor-enthaltenden radikalen für die behandlung von restenosis
AT02733745T ATE415975T1 (de) 2001-05-28 2002-05-28 Verwendung einer verbindung mit einer negativ geladenen domäne von phosphor-enthaltenden radikalen für die behandlung von restenosis
US10/478,962 US20040235799A1 (en) 2001-05-28 2002-05-28 Use of a compound with a negatively charged domain of radicals for the treatment of restenosis
PCT/SE2002/001016 WO2002096436A1 (en) 2001-05-28 2002-05-28 The use of a compound with a negatively charged domain of radicals for the treatment of restenosis
DK02733745T DK1390045T3 (da) 2001-05-28 2002-05-28 Anvendelse af en forbindelse med et negativt ladet domæne af phosphorholdige radikaler til behandling af restenose
EP02733745A EP1390045B1 (de) 2001-05-28 2002-05-28 Verwendung einer verbindung mit einer negativ geladenen domäne von phosphor-enthaltenden radikalen für die behandlung von restenosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101854A SE0101854L (sv) 2001-05-28 2001-05-28 Användning av en förening med en negativt laddad region av grupper för behandling av restenos.

Publications (2)

Publication Number Publication Date
SE0101854D0 SE0101854D0 (sv) 2001-05-28
SE0101854L true SE0101854L (sv) 2002-11-29

Family

ID=20284248

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101854A SE0101854L (sv) 2001-05-28 2001-05-28 Användning av en förening med en negativt laddad region av grupper för behandling av restenos.

Country Status (9)

Country Link
US (1) US20040235799A1 (de)
EP (1) EP1390045B1 (de)
JP (1) JP2004532872A (de)
AT (1) ATE415975T1 (de)
DE (1) DE60230134D1 (de)
DK (1) DK1390045T3 (de)
ES (1) ES2316568T3 (de)
SE (1) SE0101854L (de)
WO (1) WO2002096436A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20021570A0 (fi) * 2002-09-03 2002-09-03 Gallen Kallela Siren Janne Päällystetyn kirurgisen stentin paranneltu rakenne
US10159297B2 (en) * 2013-05-21 2018-12-25 Bradford C. Jamison Patterned plexus of filaments, method of producing and articles containing patterned filaments

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
IT1275935B1 (it) * 1995-03-17 1997-10-24 Chiesi Farma Spa Derivato di aminotetralina per la terapia di malattie cardiovascolari
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
CA2166155C (en) * 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
AUPO888497A0 (en) * 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
US6896659B2 (en) * 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
AU6409499A (en) * 1998-10-01 2000-04-17 Children's Medical Center Corporation Method of treatment of cardiovascular injuries
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US7019108B2 (en) * 2001-06-01 2006-03-28 University Of Southern California Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
WO2004096832A2 (en) * 2003-04-29 2004-11-11 Children's Medical Center Corporation Novel antiangiogenic peptides
JP3958309B2 (ja) * 2004-08-23 2007-08-15 株式会社名機製作所 射出成形機

Also Published As

Publication number Publication date
EP1390045A1 (de) 2004-02-25
EP1390045B1 (de) 2008-12-03
SE0101854D0 (sv) 2001-05-28
ES2316568T3 (es) 2009-04-16
WO2002096436A1 (en) 2002-12-05
ATE415975T1 (de) 2008-12-15
DK1390045T3 (da) 2009-02-23
DE60230134D1 (de) 2009-01-15
JP2004532872A (ja) 2004-10-28
US20040235799A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
DE50310516D1 (de) Fredericamycin-derivate
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
BG106586A (en) Pyrazolopyramidines as therapeutic agents
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
MY140031A (en) Carbonyl compounds
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
SE0301232D0 (sv) Novel use
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
DK1390371T3 (da) Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer
DK0725637T3 (da) Parenteralt busulfan til behandling af malign sygdom
SE9802208D0 (sv) Novel compounds
DK1030667T3 (da) Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
BRPI0416289A (pt) 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)
SE0200198D0 (sv) New use
SE0101854L (sv) Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
SE9802209D0 (sv) Novel compounds
ATE273006T1 (de) Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
SE0002739D0 (sv) New use
DK0850062T3 (da) Anvendelse af halofuginon til fremstilling af et medikament til svækkelse af neovaskularisering og til behandling af maligne tumorer hos mennesker
SE0004827D0 (sv) Therapeutic compounds

Legal Events

Date Code Title Description
NAV Patent application has lapsed